What Reliant AI does

Reliant AI was a Canadian applied-AI company that built domain-specific generative AI tooling for the biopharma industry. Its flagship product, Reliant Tabular, was an AI workbench that automated systematic literature reviews, competitive landscaping, evidence synthesis, and clinical trial analytics for pharmaceutical and biotechnology companies and the consulting firms that serve them. The platform combined proprietary fine-tuned large language models (including a fine-tuned version of Llama 3.1 70B), reinforcement learning, retrieval-augmented generation, and "densified knowledge graphs" covering 38M+ scientific publications, conference abstracts, and clinical trials, with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference databases.

The company was founded in 2023 in Montreal and Berlin by Karl Moritz Hermann (former DeepMind senior staff researcher), Marc G. Bellemare (former Google Brain/DeepMind, Canada CIFAR AI Chair at Mila), and Richard Schlegel (former EY-Parthenon Life Sciences Strategy). It raised $11.3M in seed funding in August 2024, co-led by Tola Capital and Inovia Capital, with additional participation from Mike Volpi, Amit Agarwal, and Yoshua Bengio; total disclosed funding reached $13.5M. By the time of acquisition the team was approximately 30 people operating across Montreal, Berlin, Boston, Denver, and London.

Reliant AI monetized through enterprise SaaS subscriptions for Reliant Tabular, milestone-based professional services, and Integration Partnership engagements with named customers including GSK, Kyowa Kirin, Ipsen, OMass Therapeutics, Medicus Pharma, and life sciences consulting firms such as Hayden Consulting Group. On May 19, 2026, Reliant AI was acquired by Cohere Inc., and the company, its biomedical datasets, and its workbench were integrated into Cohere's "North for Pharma" agentic AI platform; co-founders Hermann and Bellemare became vice presidents at Cohere.

Name

Reliant AI

Legal name

Reliant AI, Inc.

Website

https://reliant.ai

Company type

Private

Founded year

2023

Operating status

Acquired

Headcount range

1–10 employees

Short description

Reliant AI built Reliant Tabular, an AI workbench that automates systematic literature reviews, competitive landscaping, and clinical trial analytics for biopharma companies and life sciences consultancies. The Montreal-based company was acquired by Cohere in May 2026.

Ownership category

akta.pro rank

Product category

Biopharma AI Analytics Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Biopharma data analytics
• Life sciences AI
• Systematic literature reviews
• Competitive intelligence software
• Clinical trial analytics

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Enterprise SaaS subscriptions for Reliant Tabular: Recurring subscriptions to the Reliant Tabular workbench with flexible and scalable pricing tailored to team needs, including unlimited extractions, abstracts, and systematic literature reviews across all plans.
2. Enterprise custom deployment and integration partnerships: Custom enterprise deployment engagements that include bespoke data pipeline integration, use-case specific benchmarking, and feature prioritization; offered via internal deployment or API access as Integration Partnerships.
3. Milestone-based professional services engagements: One-year milestone-based services agreements for tailored use cases (e.g., Medicus Pharma engagement capped at $200,000 for an AI-driven clinical data analytics platform supporting trial execution).
4. White paper, blog and trend-report content marketing to drive inbound pipeline: Free published research, white papers, blogs, and a paid 2026 Life Sciences AI Trend Report used as a top-of-funnel demand generation and lead capture mechanism.

Pricing tiers

Go-to-market motion5 records

Distribution channels4 records

Marketing channels10 records

Core offering

Reliant AI provides Reliant Tabular, a generative-AI-powered data analytics workbench purpose-built for the biopharma industry. The platform automates systematic literature reviews, competitive landscaping, asset benchmarking, clinical trial site selection, and structured scientific data extraction by combining proprietary fine-tuned large language models with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. The platform is delivered as enterprise SaaS with an enterprise tier offering custom data pipelines, data lake integration, and API/internal deployment for bespoke life sciences workflows.

Product overview

Reliant AI offers a single integrated AI product platform anchored by Reliant Tabular, an applied-AI workbench purpose-built for the life sciences industry. Reliant Tabular is the core platform that combines proprietary generative AI and machine learning pipelines (including fine-tuned large language models) with native data integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. On top of this core platform, Reliant AI delivers two primary use-case modules: an Evidence Synthesis / Literature Reviews module for systematic, targeted, and rapid literature reviews with risk of bias assessment, and a Competitive Landscaping module for forecasting, asset benchmarking, and competitive intelligence. These modules are complemented by an Enterprise Offering & Integration Partnerships tier that provides custom data pipelines, data lake integration, and API access for bespoke deployments. Reliant AI also publishes research, including its 2026 Life Sciences AI Trend Report. Following Cohere's May 2026 acquisition, Reliant Tabular's technology and team have been folded into Cohere's "North for Pharma" agentic AI system for biopharma workflows.

Differentiator

Problem solved

Functional benefit

Brands

• Reliant Tabular: AI workbench for biopharma analysts designed to automate systematic literature reviews, evidence-based decision-making, competitive landscaping, and data extraction for pharmaceutical and biotechnology industries.

Products and services

• Reliant Tabular Reliant Tabular is Reliant AI's flagship generative-AI-powered data analytics workbench for the biopharma industry. It automates systematic literature reviews, competitive landscaping, asset benchmarking, and structured scientific data extraction for life sciences teams, with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. Sold to enterprise and mid-market biopharma, biotech, and life sciences consulting teams.
• Enterprise Offering & Integration Partnerships Enterprise tier of Reliant Tabular offering custom data pipelines for data lake integration, adaptation to enterprise IT security and audit requirements, and bespoke use-case workflows and templates. The Integration Partnerships tier adds internal deployment or API access with feature prioritization and custom data integration configurations. Sold to large pharmaceutical and biotech enterprises.

Quantifiable outcome

• 200x faster than manual methods for systematic literature reviews (oncology case study)
• +9 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability10 records

Feature7 records

Partnerships

Two partnerships are on record, tiered acquirer / parent company and strategic pilot partner.

• Cohereacquirer / parent companyStrategic or Co-development Partner · 19 May 2026Acquired Reliant AI on May 19, 2026 to expand into biopharma and healthcare. Reliant AI's research team, proprietary biomedical datasets, and Reliant Tabular workbench are being integrated into Cohere's enterprise AI platform as 'North for Pharma'; co-founders Karl Moritz Hermann and Marc Bellemare became Cohere VPs.
• Medicus Pharmastrategic pilot partnerStrategic or Co-development Partner · 22 December 2025Non-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for trial execution. Initial one-year, milestone-based services engagement capped at $200,000 focused on dynamic site selection and patient stratification for a Teverelix clinical study planned for 2026, with potential expansion to a larger late-stage study in 2028.

Scale indicators16 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Elicit: Elicit is an AI research assistant that automates literature review and evidence synthesis for scientists. Reliant AI's website explicitly publishes a competitor-comparison page against Elicit, positioning Tabular as the domain-specialized alternative for biopharma systematic literature reviews.
• Causaly: Causaly is an AI platform for biomedical research that builds knowledge graphs over scientific literature to support drug discovery and competitive intelligence. It overlaps directly with Reliant Tabular's densified knowledge graphs and competitive-landscaping workflows for pharma.
• Iris.ai: Iris.ai provides an AI engine for scientific text analysis and R&D knowledge management. Like Reliant, it targets enterprise R&D teams with tools for literature review, patent analysis, and structured data extraction across scientific publications.
• Scite (scite.ai): Scite uses AI to classify and contextualize scientific citations, helping researchers evaluate evidence. Like Reliant, it sits in the AI-for-literature-review category used by biopharma analysts and competes for the same end-user workflow.

Broad incumbents

• Owkin: Owkin is an AI biotech company applying machine learning to clinical research and drug development for major pharma partners. It sits in the same biopharma-AI category as Reliant but operates a broader federated-learning and trial-optimization platform rather than a literature workbench.
• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company combining generative chemistry, biology, and clinical trial analytics. It competes with Reliant in pharma AI workflows but spans the full discovery-to-clinic value chain rather than focusing on evidence synthesis.
• BenevolentAI: BenevolentAI applies knowledge graphs and machine learning to drug discovery and development for pharma. It overlaps with Reliant's biomedical knowledge-graph approach but is positioned further upstream in target identification and pipeline prioritization.
• IQVIA: IQVIA is the world's largest life-sciences analytics and clinical research services provider, with AI-augmented offerings spanning evidence synthesis, competitive intelligence, and clinical trial design. Reliant targets IQVIA-style use cases with a more focused, AI-native workbench.
• Tempus Labs: Tempus is an AI-powered precision medicine company combining clinical and molecular data for pharma and providers. It competes with Reliant in pharma-facing AI analytics (especially trial site selection and patient stratification) but at much greater scale.
• Veeva Systems: Veeva is the dominant cloud-software platform for the global life-sciences industry, spanning commercial, clinical, regulatory, and data workflows. Several Reliant employees came from Veeva, and Veeva's data-and-AI portfolio overlaps with Reliant's competitive-landscaping and trial use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reliant AI